Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Laekna Therapeutics Shanghai Co. Ltd.

www.laeknatp.com

Latest From Laekna Therapeutics Shanghai Co. Ltd.

Start-Up Quarterly Statistics: Q3 Financings Slump Despite Large Gossamer Series B, Big Rubius IPO

Third quarter biopharma start-up financing activity decreased from the record-breaking Q2. A review of biopharma start-up dealmaking and financing activity from July through September 2018, based on data from Strategic Transactions.

Deals StartUps and SMEs

Deal Watch: Harbour Expands Horizons Beyond China

Antibody developer Harbour Biomed signs its first deal for rights outside China in cancer pact with Kelun. Portage buys SalvaRx to increase its immuno-oncology capabilities, while Paragon spinout Emalex will take over Psyadon’s pediatric Tourette syndrome program.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Laekna Therapeutics Shanghai Co. Ltd.
  • Senior Management
  • Chris Xiangyang Lu, PhD, CEO
    Amy Xie, VP, Operations
  • Contact Info
  • Laekna Therapeutics Shanghai Co. Ltd.
    866 Halei Rd., Zhangjiang
    Ste. 305
    Shanghai, 201203
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register